Advancements in the delivery of chimeric antigen receptor (CAR) T-cell therapy have created growing urgency to expand access across diverse care settings. Since the FDA approved the first two CAR T-cell therapies in 2017 for acute lymphoblastic leukemia and non-Hodgkin lymphoma, the field has expanded to six approved therapies for certain hematologic malignancies.
These therapies have demonstrated the potential for durable remission and improved survival in patients with relapsed or refractory disease, while research continues to explore applications in solid tumors.
ACCC is supporting community cancer programs and practices by providing education and tools to strengthen care coordination, address implementation challenges, and help identify eligible patients for CAR T-cell therapy earlier in their treatment journey.
Discover the top barriers, facilitators, and opportunities shaping access to CAR T-cell therapy, including how programs can turn challenges into solutions.
This program is made possible by support from Kite Pharma, Johnson & Johnson Healthcare Inc., and Legend Biotech.
